Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot phase 2 study of alendronate to prevent pelvic insufficiency fractures in cervical cancer patients receiving chemoradiotherapy
MOH_2024-11-13_013715Phase 2Not yet recruiting
- Sponsor
- ד"ר אכרם סעד
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alendronate in Cervical Cancer (CC), sponsored by ד"ר אכרם סעד. Primary endpoint: Incidence of pelvic insufficiency fractures at 2 years. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
alendronate
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on MOH_2024-11-13_013715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-13_013715.